| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB |
ACTRN12623000141640: Investigating the effect of Romosozumab on osteoporosis following spinal cord injury |
|
|
| Not yet recruiting | 4 | 30 | | | Princess Alexandra Hospital, Metro South Health, Princess Alexandra Hospital | Osteoporosis, Acute Spinal Cord Injury | | | | |
ACTRN12623000867695: Combining bone-building medication with bone-building exercise in postmenopausal women with low bone mass |
|
|
| Recruiting | 4 | 102 | | | Royal North Shore Hospital, Healthy Bones Australia, Avant Mutual, NORTH Foundation | osteopenia, osteoporosis | | | | |
NCT04091243: Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users |
|
|
| Completed | 4 | 70 | RoW | Romosozumab | Tuen Mun Hospital | Glucocorticoid-induced Osteoporosis | 10/23 | 11/23 | | |
NCT04597931: Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density |
|
|
| Not yet recruiting | 4 | 30 | NA | Romosozumab, Zoledronic Acid | Sheba Medical Center | Osteoporosis Fracture, Spinal Cord Injuries | 11/23 | 11/23 | | |
NCT05010590: Anabolic Therapy in Postmenopausal Osteoporosis |
|
|
| Active, not recruiting | 4 | 50 | US | Romosozumab, Denosumab | Massachusetts General Hospital | Postmenopausal Osteoporosis | 05/25 | 05/25 | | |
NCT06472050: Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study |
|
|
| Recruiting | 4 | 63 | RoW | Romosozumab, Evenity (brand names), Denosumab, Prolia (brand name) | Tuen Mun Hospital | Osteoporosis, Glucocorticoids Toxicity | 12/25 | 03/26 | | |
MORD, NCT06720350: Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures |
|
|
| Not yet recruiting | 4 | 60 | RoW | Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia) | Marmara University | Osteoporosis in Post-menopausal Women | 10/26 | 12/26 | | |
NCT05180032: Treatment With Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI |
|
|
| Recruiting | 4 | 39 | US | Romoszumab, Evenity, Denosumab, Prolia, Placebo | James J. Peters Veterans Affairs Medical Center, Kessler Institute for Rehabilitation | Osteoporosis, Spinal Cord Injuries | 03/25 | 03/27 | | |
| Not yet recruiting | 4 | 50 | US | Romosozumab, Evenity, Teriparatide, Forteo | Massachusetts General Hospital, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Osteoporosis, Postmenopausal, Osteoporosis | 04/27 | 01/28 | | |
NCT05101018: Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI |
|
|
| Active, not recruiting | 4 | 40 | US | Romosozumab, Evenity, Denosumab, Prolia | James J. Peters Veterans Affairs Medical Center, Kessler Institute for Rehabilitation | Osteoporosis, Spinal Cord Injuries | 11/25 | 11/27 | | |
NCT06079476: A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. |
|
|
| Active, not recruiting | 4 | 100 | RoW | Romosozumab | Amgen | Postmenopausal Osteoporosis | 10/25 | 10/25 | | |
| Recruiting | 4 | 270 | Europe | Romosozumab, Evenity, Zoledronate | University of Aarhus | Osteoporosis | 08/26 | 08/26 | | |
| Recruiting | 4 | 200 | US | Romosozumab, Evenity, Placebo, Zoledronic acid, Reclast, Calcium and Vitamin D | Susan L. Greenspan, National Institutes of Health (NIH), National Institute on Aging (NIA) | Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture | 09/27 | 09/27 | | |
NCT05067335: A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis |
|
|
| Completed | 3 | 327 | RoW | Romosozumab, Placebo | UCB Biopharma SRL | Osteoporosis | 11/23 | 11/23 | | |
NCT04779216: Effects of Romosozumab on Bone Density in Women with Anorexia Nervosa |
|
|
| Active, not recruiting | 3 | 30 | US | Romosozumab Prefilled Syringe, Placebo, Alendronate 70Mg Tab | Karen Klahr Miller, MD, Amgen | Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders | 10/24 | 10/25 | | |
NCT06533865: Romosozumab As an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea |
|
|
| Not yet recruiting | 3 | 114 | NA | Romosozumab, Evenity, Placebo, Zoledronic acid, Zoledronate, Reclast | Massachusetts General Hospital | FHA (Functional Hypothalamic Amenorrhea) | 12/28 | 06/29 | | |
NCT05972551: Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta |
|
|
| Recruiting | 3 | 106 | Europe, Canada, Japan, US, RoW | Romosozumab, EVENITY®, Bisphosphonate | Amgen | Osteogenesis Imperfecta | 02/27 | 05/27 | | |
ACTRN12624000027516: Romosozumab for Patients with Multiple Myeloma with Skeletal Events on Zoledronic Acid: A Pilot Study |
|
|
| Recruiting | 2 | 12 | | | St Vincent's Hospital, Sydney, Tour De Cure | Multiple myeloma | | | | |
NCT04232657: Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI |
|
|
| Active, not recruiting | 2 | 36 | US | Romosozumab, Evenity, Denosumab, Prolia, Placebo, Normal Saline (NS) injection | VA Office of Research and Development, Kessler Institute for Rehabilitation | Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI | 02/26 | 03/27 | | |
| Completed | 2 | 12 | US | Romosozumab, Evenity, Alendronate, Fosamax | Northwestern University, Amgen | Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries, Chronic Spinal Paralysis | 06/24 | 06/24 | | |
NCT04800367: Romosozumab/Denosumab Study for Premenopausal IOP |
|
|
| Recruiting | 2 | 30 | US | Romosozumab Prefilled Syringe [Evenity], Evenity, Denosumab 60 MG/ML Prefilled Syringe [Prolia], Prolia | Columbia University, Amgen | Premenopausal Idiopathic Osteoporosis | 03/25 | 03/26 | | |
| Completed | 1 | 25 | Europe, US, RoW | Romosozumab, Calcium, Vitamin D | Amgen | Osteogenesis Imperfecta | 03/23 | 03/23 | | |
NCT05775094: A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis |
|
|
| Active, not recruiting | 1 | 10 | US | Romosozumab | Memorial Sloan Kettering Cancer Center | Osteoporosis, Multiple Myeloma | 03/26 | 03/26 | | |
| Recruiting | N/A | 150 | Europe | Zoledronate, zoledronic acid; zolendronate, Denosumab, Dmab, Teriparatide, TPTD, Romosozumab, Romo | 424 General Military Hospital | Osteoporosis, Postmenopausal | 12/25 | 12/25 | | |
